Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Millennium Management Llc Purchases 6,005 Shares of Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Millennium Management Llc acquired 6,005 shares of the business’s stock in a transaction dated Tuesday, March 31st. The shares were bought at an average price of $28.16 per share, with a total value of $169,100.80. Following the transaction, the insider directly owned 146,657 shares in the company, valued at approximately $4,129,861.12. The trade was a 4.27% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Millennium Management Llc also recently made the following trade(s):

• On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $28.12, for a total value of $52,218.84.
• On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.81, for a total value of $13,539.05.
• On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.61, for a total value of $23,629.68.
• On Monday, March 30th, Millennium Management Llc acquired 9,533 shares of Sensei Biotherapeutics stock. The shares were bought at an average price of $25.86 per share, with a total value of $246,523.38.
• On Friday, March 27th, Millennium Management Llc acquired 15,321 shares of Sensei Biotherapeutics stock. The shares were bought at an average price of $26.61 per share, with a total value of $407,691.81.
• On Thursday, March 26th, Millennium Management Llc bought 5,731 shares of Sensei Biotherapeutics stock. The shares were purchased at an average cost of $28.62 per share, for a total transaction of $164,021.22.
• On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $25.49, for a total transaction of $40,554.59.
• On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $31.65, for a total transaction of $36,397.50.
• On Wednesday, April 1st, Millennium Management Llc bought 6,175 shares of Sensei Biotherapeutics stock. The shares were purchased at an average cost of $34.49 per share, for a total transaction of $212,975.75.
• On Thursday, April 2nd, Millennium Management Llc sold 7,666 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $32.12, for a total transaction of $246,231.92.

Sensei Biotherapeutics Stock Up 3.1%

Shares of NASDAQ:SNSE opened at $20.43 on Friday. The company’s fifty day moving average is $28.89 and its two-hundred day moving average is $17.87. Sensei Biotherapeutics, Inc. has a 12-month low of $5.25 and a 12-month high of $36.76. The company has a market cap of $27.38 million, a P/E ratio of -1.23 and a beta of -0.18.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($130.83). Equities research analysts anticipate that Sensei Biotherapeutics, Inc. will post -2.77 earnings per share for the current year.

Trending Headlines about Sensei Biotherapeutics

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Analyst Ratings Changes

A number of research firms have recently weighed in on SNSE. Zacks Research raised shares of Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Friday, April 24th. Leerink Partners initiated coverage on shares of Sensei Biotherapeutics in a research report on Monday, April 20th. They set an “outperform” rating and a $50.00 target price on the stock. Finally, Wall Street Zen downgraded shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $40.00.

Hedge Funds Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC boosted its holdings in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 178.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 32,041 shares of the company’s stock after buying an additional 20,525 shares during the quarter. Renaissance Technologies LLC owned about 2.39% of Sensei Biotherapeutics worth $1,010,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.